NCT00963703View on ClinicalTrials.gov

Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Rituximab

Rituximab 1000 mg Intravenously day 1 and day 15

Trial Locations (1)

R3A 1M4

Arthritis Centre, University of Manitoba, Winnipeg

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University of Manitoba

OTHER

NCT00963703 - Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter